Every Form 4 that Phio Pharmaceuticals Corp. (PHIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PHIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHIO filings page.
Phio Pharmaceuticals Corp. (PHIO) director Ronald Todd Plott reported direct purchases of 5,000 common shares on September 28, 2026, at $1.03 per share and 5,000 shares on September 29, 2026, at $1.04 per share. The Rule 10b5-1 plan checkbox was unchecked.
Phio Pharmaceuticals Corp. Chief Financial Officer Lisa Cabott Carson received an award covering 108,000 shares on September 28, 2026. Her reported holdings after the award were 189,112 shares, including shares of common stock underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. reported that Chairman, Pres. & CEO Robert J. Bitterman received a grant covering 400,000 common shares underlying restricted stock units on September 28, 2026. The underlying shares will vest on the first annual anniversary of the grant. His reported post-transaction holdings were 764,871 shares, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. director Ronald Todd Plott received a grant covering 17,000 shares underlying restricted stock units on September 28, 2026. The transaction was reported as a direct grant/award acquisition. His reported direct holdings following the transaction were 32,000 shares, including common stock underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. director Patricia A. Bradford purchased 6,500 shares of common stock on September 24, 2026, at $1.0127 per share. Her reported direct holdings after the purchase were 64,151 shares, including shares of common stock underlying unvested restricted stock units. No Rule 10b5-1 plan is reported for the purchase.
Phio Pharmaceuticals Corp. reported that Chairman, President and CEO Robert J. Bitterman purchased 2,000 common shares on September 22, 2026, at $1.0289 per share. His reported direct holdings after the purchase were 364,871 shares, including common stock underlying unvested restricted stock units. No Rule 10b5-1 plan is reported.
Phio Pharmaceuticals Corp. (PHIO) director Patricia A. Bradford purchased common stock on September 15, 2026. She bought 12,000 shares of common stock at $1.03 per share in an open-market or private transaction, increasing her direct holdings to 57,651 shares, which includes shares underlying unvested restricted stock units.
No Rule 10b5-1 trading plan is reported for this transaction.
Phio Pharmaceuticals Corp. (PHIO) reported a Form 4 for Chief Financial Officer Lisa Cabott Carson showing a disposition related to tax withholding. On September 11, 2026, the issuer withheld 12,888 shares of common stock at $1.03 per share to satisfy her tax withholding obligations upon vesting of restricted stock units; no shares were sold in the market. After this transaction, she held 81,112 shares directly, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. (PHIO) reported that Chairman, President & CEO Robert J. Bitterman had 68,550 shares of common stock withheld on September 11, 2026 to satisfy tax withholding obligations related to vesting restricted stock units. No shares were sold, and he now directly holds 362,871 shares, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. (PHIO) director Ronald Todd Plott reported an open-market or private purchase of company stock. On 2026-08-19, he bought 15,000 shares of common stock at $1.14 per share. Following this transaction, he directly holds 15,000 shares of Phio Pharmaceuticals common stock.
Phio Pharmaceuticals Corp. (PHIO) reported that Chairman, President and CEO Robert J. Bitterman purchased 10,000 shares of common stock on August 18, 2026, in an open-market or private transaction at $1.06 per share. Following this transaction, he directly holds 431,421 shares, which include shares underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. Chairman, President and CEO Robert J. Bitterman reported an open-market purchase of common stock. On June 26, 2026, he bought 10,000 shares at $0.99 per share. Following this transaction, he directly owns 421,421 shares, which include shares underlying unvested restricted stock units.
Phio Pharmaceuticals director Curtis Lockshin received an equity award in the form of restricted stock units. On February 5, 2026, he was granted 16,600 shares of common stock at a price of $0 per share, reflecting a stock-based compensation grant rather than a purchase.
The filing states these shares represent a restricted stock unit award that will vest on the first anniversary of the grant. Following this grant, Lockshin beneficially owns 35,155 shares of Phio Pharmaceuticals common stock in direct ownership, including shares underlying unvested restricted stock units that have been adjusted for prior reverse stock splits.
Phio Pharmaceuticals director Jonathan E. Freeman received a new equity grant. On 02/05/2026, he was awarded 16,600 shares of common stock at a price of $0, in the form of restricted stock units that will vest on the first anniversary of the grant.
After this award, Freeman beneficially owns 32,655 shares, which include shares underlying unvested restricted stock units. The reported share amounts have been adjusted to account for prior reverse stock splits.
Phio Pharmaceuticals director David H. Deming reported an equity award of 23,800 shares of common stock underlying restricted stock units on February 5, 2026. The filing shows the award was recorded at a price of $0 per share and coded as an acquisition.
These restricted stock units will vest on the first anniversary of the grant, and the total beneficial ownership after this transaction is 37,800 shares held directly, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals reported an equity award to its Chief Financial Officer, Lisa Carson. On 02/05/2026, she received 47,000 shares of common stock for $0, representing a restricted stock unit grant that will vest on the first anniversary of the grant. Following this award, she beneficially owns 94,000 shares of Phio common stock, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals director Patricia A. Bradford received 18,500 shares of common stock underlying a restricted stock unit award on February 5, 2026. These shares will vest on the first anniversary of the grant. After this award, she beneficially owns 45,651 common shares directly, including unvested restricted stock units, with amounts adjusted for prior reverse stock splits.
Phio Pharmaceuticals’ Chairman, President and CEO Robert J. Bitterman received 120,000 shares of common stock on February 5, 2026 through a restricted stock unit (RSU) grant. The Form 4 shows the shares were acquired at a price of $0 per share, reflecting an equity award rather than an open‑market purchase.
The 120,000 shares represent RSUs that will vest on the first anniversary of the grant. After this award, Bitterman beneficially owns 411,421 shares of Phio common stock in direct ownership, which includes shares underlying unvested RSUs.
Phio Pharmaceuticals Corp. (PHIO) reported an insider stock purchase by its Chairman, President and CEO, who is also a director. On 11/21/2025, the executive bought 5,000 shares of common stock at a price of $1.14 per share in an open-market transaction coded as a purchase.
After this transaction, the executive beneficially owns 281,421 shares of Phio common stock, which includes shares underlying unvested restricted stock units. The filing was made as a Form 4 by a single reporting person, indicating a change in that individual’s ownership position in the company.
Phio Pharmaceuticals Corp. (PHIO) reported an insider purchase by its Chairman, President and CEO. On 11/18/2025, the executive, who also serves as a director, bought 5,000 shares of Phio common stock at a price of $1.27 per share in an open-market transaction coded "P" for purchase.
After this transaction, the reporting person beneficially owned 276,421 shares of common stock, which includes shares underlying unvested restricted stock units. All reported holdings are listed as directly owned.